# Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

> **NCT05158296** · PHASE2,PHASE3 · TERMINATED · sponsor: **Laboratoires Thea** · enrollment: 7 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders

## Interventions

- **DRUG:** Ultevursen
- **OTHER:** Sham-procedure

## Key facts

- **NCT ID:** NCT05158296
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-08
- **Primary completion:** 2022-10-12
- **Final completion:** 2022-10-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05158296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05158296, "Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05158296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*